cme institute logo
mobile menu trigger

Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD

CME Journal Supplement Provided by CME Institute
Volume 84 | 2023 | Supplement 1

Supported by an unrestricted educational grant from Sage Therapeutics, Inc.

Now that you’ve read the print supplement, continue here to watch Kristina M. Deligiannidis, MD and Anita H. Clayton, MD discuss MDD and PPD. At the end of this page, click to complete the posttest to earn free AMA PRA Category 1 credit.

Inadequacies of Suboptimal Depression Treatment

Click to take the Posttest

Underlying Neurobiology of MDD and PPD

Click to take the Posttest

Clinical Trial Data for Approved and Emerging GABA-targeting Neuroactive Steroids

Click to take the Posttest